1. In Vivo
  2. >>Business Strategy

Cardiac Cell Therapy: Are There Easier Ways to Restore Function? Probably

Discussions at the Transcatheter Cardiovascular Therapeutics meeting reinforced the notion that too little is known about cardiac cell therapy to usefully proceed with large-scale studies. Some suggested it'd be more useful to focus on small-molecule or device-oriented approaches to restoring contractile function.

The first ever controlled clinical trials of cardiac cell therapies have yielded only equivocal results: some showed marginal success, others either disappointed or failed outright. A provocative discussion among thought leaders at the October 2006 Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC, reinforced the notion that too little is known about which cell types, doses, and administration routes are most feasible in order to usefully proceed with large-scale studies. A few experts went so far as to suggest eschewing this difficult therapy entirely, in favor of small-molecule or device-oriented approaches to restoring contractile function in the heart—the goal of treatment.

The results of two European trials were most troubling. Previously reported early results from the randomized BOOST study at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.